The use of transcatheter mitral valve intervention for the treatment of mitral valve regurgitation (MR) continues to evolve; at present guidelines only recommend it for inoperable or high surgical risk patients. So far, many devices have been assessed, some of which have shown promising results, but only for poor surgical candidates. Researchers looked into the<a href="https://solaci.org/en/2024/03/15/tender-study-evolution-at-one-year/" title="Read more" >...</a>
Relive the traditional Contest for Young Interventional Cardiologists at Paraguay Regional Sessions 2022. During this scientific session, carried out on June 30, 2022, 8 challenging interventional cardiology clinical studies were presented by promising young interventionists from Latin America. They were assessed by a panel of experts that also commented on the most relevant points of<a href="https://solaci.org/en/2022/09/26/paraguay-sessions-2022-relive-the-contest-for-young-interventionists/" title="Read more" >...</a>
Chronic obstructive pulmonary disease (COPD) and cardiovascular disease are associated to hospitalization and mortality. When associated to severe mitral regurgitation, not only do these two conditions have poor evolution, but they also limit the possibility of surgical valve replacement, given its high risk. Edge-to-edge repair with MitraClip has been shown beneficial in a group of<a href="https://solaci.org/en/2022/08/17/mitraclip-in-patients-with-copd-a-valid-option/" title="Read more" >...</a>
01- Surgeons’ Claim on Low-Risk Patients with Aortic Stenosis Recent randomized trials including low-risk patients showed positive results for transcatheter aortic valve replacement (TAVR) compared with surgical aortic valve replacement. Read more HERE 02- Major Cause of Myocardial Injury by COVID-19 The most common cause of myocardial necrosis in patient undergoing COVID-19 infection is microthrombi. These<a href="https://solaci.org/en/2021/04/07/the-most-read-articles-in-interventional-cardiology-of-march/" title="Read more" >...</a>
In this selection, we summarize for you the most important scientific news of 2020 in the field of structural heart disease. 01- Virtual ACC 2020 | COAPT: Better Quality of Life Translates into Harder End-Points After transcatheter mitral valve repair with MitraClip, the COAPT patients saw improved quality of life, better survival rate and fewer hospitalizations<a href="https://solaci.org/en/2020/12/17/the-most-read-articles-in-structural-heart-disease-of-2020/" title="Read more" >...</a>
Using Sapien 3, transcatheter mitral valve replacement to treat failed bioprosthetic valves can be performed with a high degree of technical success. Failed mitral bioprosthetic valves are truly challenging due to how frequent symptoms are and the high morbidity/mortality associated with a new surgical replacement. Furthermore, there are no catheter options specifically designed to treat this<a href="https://solaci.org/en/2020/12/09/sapien-3-performs-well-in-jobs-for-which-it-is-not-designed/" title="Read more" >...</a>
The trick is to avoid testing empirically more to the right or to the left, a more caudal or cranial angular, and check what a multislice computed tomography suggests. The increase in coronary computed tomography imaging studies—due to guideline recommendations, practicality, and patient comfort—means that we frequently have these data in the cath lab even<a href="https://solaci.org/en/2020/07/14/europcr-2020-a-trick-to-find-the-perfect-projection-to-treat-ostia-or-bifurcation-lesions/" title="Read more" >...</a>
After transcatheter mitral valve repair with MitraClip, the COAPT patients saw improved quality of life, better survival rate and fewer hospitalizations for cardiac failure at long term follow-up.&nbsp; Improved quality of life had already been presented, exactly one year ago at the ACC 2019. In that occasion, it was established that the MitraClip reduces symptoms<a href="https://solaci.org/en/2020/03/25/virtual-acc-2020-coapt-better-quality-of-life-translates-into-harder-end-points/" title="Read more" >...</a>
In September 2008, interventional physicians at the Heart and Vascular Centre Hamburg conducted the first MitraClip implantation after its Conformité Européenne (CE)-marking approval. In July 2019, the same site reached an amazing milestone, 1000 MitraClips implanted, and in doing so it became the most experienced site in the world. Those 1000 patients treated had an average logistic<a href="https://solaci.org/en/2019/10/28/1000-mitraclips-results-from-the-worlds-most-experienced-site/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. Mitral regurgitation is the most frequent type of valve disease, accounting for >6% of patients over 65 years old. Surgery is currently the strategy of choice, but percutaneous treatment is a valid alternative. The long-term progress of symptomatic patients at high surgical risk who do not meet the formal indications for<a href="https://solaci.org/en/2019/02/01/good-outcomes-for-mitraclip-off-label/" title="Read more" >...</a>